Patient-Reported Quality of Life Before and After Chemoradiation for Intact Pancreas Cancer: A Prospective Registry Study
William G. Breen(Mayo Clinic in Arizona), Kenneth W. Merrell(Mayo Clinic), Mark J. Truty(Mayo Clinic in Arizona), Terence T. Sio(The University of Texas MD Anderson Cancer Center), William G. Rule(Mayo Clinic in Arizona), Nathan Y. Yu(Mayo Clinic Hospital), William S. Harmsen(Mayo Clinic), Christopher L. Hallemeier(Mayo Clinic in Arizona), Michael G. Haddock(Mayo Clinic in Arizona), M.A. Neben-Wittich(Mayo Clinic), Krishan R. Jethwa(Mayo Clinic), Jonathan B. Ashman(Mayo Clinic in Arizona), Amit Mahipal(Dana-Farber Cancer Institute), Robert C. Miller(Mayo Clinic), Grant M. Spears(Mayo Clinic in Florida)
Cited by 10
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
|Journal of Clinical Oncology|2016|859
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530